Viela Bio listed on Nasdaq
GAITHERSBURG, Md., Oct. 07, 2019 - Viela Bio, Inc. (Nasdaq: VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases and a portfolio company by Terra Magnum Capital Partners, today announced the closing of its previously announced initial public offering of 9,085,000 shares of its common stock, which includes 1,185,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the gross proceeds to Viela Bio from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $172.6 million.
Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Cowen and Company, LLC acted as the joint book-running managers for the offering. Guggenheim Securities, LLC acted as the lead manager for the offering.
Viela Bio was incorporated in 2018 as an independent inflammation- and autoimmunity-focused biotechnology company after spinning out six molecules from MedImmune, the global biologics research and development arm of AstraZeneca. Bing Yao, Ph.D., formerly Head of MedImmune’s Respiratory, Inflammation & Autoimmunity Innovative Medicines unit, serves as Viela’s Chief Executive Officer. The company has since then been backed by a number of investors including Boyu Capital, 6 Dimensions Capital, Hillhouse Capital, Temasek, Sirona Capital and Terra Magnum Capital Partners, etc. AstraZeneca remains the largest minority shareholder of Viela Bio.
The successful completion of its IPO demonstrated confidence of the investors in Viela Bio’s portfolio pipeline and its potential to deliver value to patients and investors. Terra Magnum Capital Partners will continue to invest in innovative technologies related to immunotherapies to accelerate the development and commercial launch of promising treatments.
TMCP was selected for the standing committee of HIIFB
On June 16, 2017, the Healthcare Industry Investment and Financing Branch ("HIIFB") was established in Beijing by China International Exchange Promotion Association for Medical and Healthcare ("CPAM"). Approved by the Ministry of Civil Affairs in 1987, CPAM is one of the largest and most active associations in China's healthcare industry with government background. The first standing committee of HIIFB was formed in the same day with Mr. Demin Han, Academician of Chinese Academy of Sciences elected as the honorary president and Terra Magnum Capital Partners elected as the member of the standing committee.
TMCP co-sponsored "the Hundred Talents Forum on Private Equity,
Mergers and Acquisitions" in China
On May 9, 2017, "the Hundred Talents Forum on Private Equity, Mergers and Acquisitions" was held by the Asset Management Association of China (the regulator of both public and private fund managers in China) in Shanghai. Terra Magnum Capital Partners was invited to co-sponsor this event. The founding partner of TMCP, Ms. Sha Wang also hosted the panel discussion on "Opportunities and Challenges in the M&A market" during the forum.
Ms. Sha WANG, as a key opinion leader in China M&A market, was interviewed by Yicai Media, which is a leading Economic & Finance focused media in China, sharing her points of view on investment related topics, including M&A, Private Equity investment and FoF investment, etc.
Ms. Sha Wang was invited to speak at the Tsinghua-CUHK Finance MBA Equity Investment Forum
The Tsinghua-CUHK ("Chinese University of Hong Kong") Finance MBA Equity Investment Forum was held in July 2016 by the Tsinghua University School of Economics and Management. Ms. Sha WANG was invited to speak at the forum as the Secretary General of the Private Equity and Buyout Funds at the Asset Management Association of China. Ms. Wang first discussed the role of Fund of Funds in asset allocation, with examples on strategy, asset class, geography, etc.